Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial. (SEED)

NCT02177552 Phase 2 UNKNOWN

The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.

Details

Lead sponsor	Rigshospitalet, Denmark
Phase	Phase 2
Status	UNKNOWN
Enrolment	98
Start date	2014-06
Completion	2019-11

Conditions

• Esophageal Neoplasms
• Stomach Neoplasms

Interventions

• Carboplatin
• Docetaxel
• Capecitabine
• Epirubicin
• Oxaliplatin

Primary outcomes

• The proportion of participants alive one year after randomisation — Three and a half years

Countries

Denmark